5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

February 28, 2006

Study Completion Date

December 31, 2006

Conditions
Neuroendocrine Tumors
Interventions
DRUG

continuous 5 fluouracil infusion plus long-acting octreotide

long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.

Trial Locations (7)

10015

Sebastiano Bombaci, Ivrea

10043

Anna Ferrero, Orbassano

10126

Enrica Milanesi, Torino

12037

Davide Perroni, Saluzzo

12051

Federico Castiglione, Alba

28100

Oscar Alabiso, Novara

62027

Benedetta Ferretti, San Severino Marche

All Listed Sponsors
lead

University of Turin, Italy

OTHER

NCT00953394 - 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter